Compare UXIN & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UXIN | BNTC |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.0M | 454.2M |
| IPO Year | 2018 | 2020 |
| Metric | UXIN | BNTC |
|---|---|---|
| Price | $1.15 | $12.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $27.67 |
| AVG Volume (30 Days) | ★ 236.3K | 176.7K |
| Earning Date | 04-10-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $245.77 | N/A |
| Revenue Next Year | $44.72 | N/A |
| P/E Ratio | $4.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $9.85 |
| 52 Week High | $4.18 | $16.76 |
| Indicator | UXIN | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 42.98 |
| Support Level | $1.10 | $11.36 |
| Resistance Level | $2.16 | $13.80 |
| Average True Range (ATR) | 0.06 | 0.85 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 44.83 | 16.21 |
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates a car retailer, pioneering industry transformation with production, new retail experiences, and digital empowerment in China. With its inventory-owning model, it provides customers a comprehensive transaction solution that encompasses the entire value chain, ranging from used-car acquisition, inspection, and reconditioning, warehousing, as well as pre-sales and after-sales services. The group offers high-quality and value-for-money used cars as well as superior full suites of services to customers through a reliable, one-stop, and hassle-free transaction experience. It derives revenues from retail vehicle sales, wholesale vehicle sales, and other businesses. The Group generates its revenues in China.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.